Stratification	mace.Outcome	mace.HR (95% CI)	surv.Outcome	surv.HR (95% C
06.Obesity:No		0.00 (0.00 0.05) **	_	0.75 (0.70, 0.70)
Q2 (12 – 14)	-	0.92 (0.90–0.95) **		0.75 (0.72–0.78)
Q3 (15 – 16)		0.88 (0.85–0.91) ****	-   -	0.66 (0.63–0.70)
Q4 (> 16)		0.84 (0.81–0.87) ****		0.62 (0.59–0.65)
06.Obesity:Yes	_		_	
Q2 (12 – 14)	#	0.89 (0.86–0.93) **		0.90 (0.85–0.95)
Q3 (15 – 16)	+	0.84 (0.80–0.88) ****		0.71 (0.66–0.75)
Q4 (> 16)	-	0.87 (0.83–0.91) ***	-	0.71 (0.67–0.75)
07.COPD History:No				
Q2 (12 – 14)	<b>•</b> i	0.91 (0.89–0.93) ***	+ ; ;	0.78 (0.75–0.81)
Q3 (15 – 16)	-	0.87 (0.85-0.90) ****	-	0.68 (0.65-0.71)
Q4 (> 16)	+	0.85 (0.82-0.88) ****	+	0.66 (0.63-0.69)
07.COPD History:Yes				
Q2 (12 – 14)		0.90 (0.84-0.96)		0.85 (0.80-0.91)
Q3 (15 – 16)		0.84 (0.77–0.91) **	- : :	0.68 (0.63–0.73)
Q4 (> 16)		0.86 (0.80–0.94) *	-	0.64 (0.60–0.69)
08.Hypertension History:No		0.00 (0.00 0.01)		0.01 (0.00 0.00)
Q2 (12 – 14)	!!	0.82 (0.75–0.89) *		0.64 (0.56–0.74)
Q2 (12 – 14) Q3 (15 – 16)	· · · · · · · · · · · · · · · · · · ·	0.82 (0.75–0.89)	; - <del></del> ' '	0.58 (0.49–0.68)
		•		·
Q4 (> 16)		0.75 (0.68–0.83) ***		0.53 (0.45–0.62)
08. Hypertension History: Yes	S   _		_ ; ;	
Q2 (12 – 14)	_	0.92 (0.90–0.94) ***	_	0.81 (0.79–0.84)
Q3 (15 – 16)	•	0.87 (0.85–0.90) ****	•	0.69 (0.66–0.71)
Q4 (> 16)	*	0.86 (0.84–0.89) ****	*	0.66 (0.64–0.69)
09.T2DM History:No				
Q2 (12 – 14)	<del> </del>	0.91 (0.89-0.94) **		0.74 (0.71-0.78)
Q3 (15 – 16)	-	0.87 (0.84-0.90) ****	-	0.62 (0.58-0.65)
Q4 (> 16)	-	0.86 (0.83-0.90) ****	-	0.63 (0.59-0.66)
09.T2DM History:Yes				
Q2 (12 – 14)	+	0.91 (0.87–0.94) **	+	0.87 (0.83-0.91)
Q3 (15 – 16)	+ ; ;	0.86 (0.82–0.90) ****	- ; ;	0.75 (0.71–0.79)
Q4 (> 16)	-	0.84 (0.81–0.88) ****	-	0.69 (0.65–0.72)
10.MACE History:No		0.04 (0.01 0.00)		0.00 (0.00 0.12)
Q2 (12 – 14)		0.91 (0.89–0.93) ***	-	0.69 (0.66–0.73)
·				
Q3 (15 – 16)		0.87 (0.84–0.89) ****	- ! !	0.63 (0.59–0.67)
Q4 (> 16)		0.85 (0.83–0.88) ****		0.64 (0.61–0.68)
10.MACE History:Yes				
Q2 (12 – 14)				0.88 (0.85–0.92)
Q3 (15 – 16)				0.72 (0.68–0.75)
Q4 (> 16)				0.67 (0.64–0.71)
11.Hypersomnia:No				
Q2 (12 – 14)	<b>■</b> i	0.91 (0.89–0.93) ***	• ! !	0.80 (0.77–0.83)
Q3 (15 – 16)	•	0.86 (0.84–0.89) ****	•	0.68 (0.65-0.70)
Q4 (> 16)	-	0.85 (0.82-0.87) ****	-	0.65 (0.63-0.68)
11.Hypersomnia:Yes	1 1 1		1 1 1	
Q2 (12 – 14)		→ 1.80 (1.30–2.49)	-	1.14 (0.76–1.71)
Q3 (15 – 16)		→ 1.24 (0.82–1.86)		1.02 (0.66–1.57)
Q4 (> 16)		→ 1.61 (1.11–2.32)	-	0.65 (0.40–1.04)
12.Insomina:No		, ,		,
Q2 (12 – 14)	-	0.92 (0.90–0.94) ***	-	0.81 (0.79–0.84)
Q3 (15 – 16)	-	0.86 (0.84–0.89) ****	-	0.69 (0.66–0.71)
Q4 (> 16)	<b>.</b>	0.84 (0.82–0.87) ****	-	0.67 (0.64–0.69)
, ,		0.04 (0.02-0.01)		0.07 (0.04-0.09)
12.Insomina:Yes		0.06 (0.70, 0.05)		0.60 (0.04, 0.70)
Q2 (12 – 14)	- I I	0.86 (0.78–0.95)		0.69 (0.61–0.79)
Q3 (15 – 16)		0.97 (0.86–1.10)	-	0.54 (0.46–0.63)
Q4 (> 16)	· ·	0.98 (0.87–1.11)	, <del></del> , ,	0.46 (0.39–0.54)
	0.1 0.5 1 1.2		0.1 0.5 1 1.2	2
	0.1 0.5 11.2		0.1 0.0 1 1.2	